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In recent years, immunotherapy has shown considerable promise in the management of 
several malignancies. However, the majority of preclinical studies have been conducted 
in rodents, the results of which often translate poorly to patients given the substantial 
differences between murine and human immunology. As the porcine immune system is 
far more analogous to that of humans, pigs may serve as a supplementary preclinical 
model for future testing of such therapies. We have generated the genetically modified 
Oncopig with inducible tumor formation resulting from concomitant KRASG12D and
TP53R167H mutations under control of an adenoviral vector Cre-recombinase (AdCre).
The objective of this study was to characterize the tumor microenvironment in this
novel animal model with respect to T-cell responses in particular and to elucidate the 
potential use of Oncopigs for future preclinical testing of cancer immunotherapies. In 
this study, we observed pronounced intratumoral T-cell infiltration with a strong CD8β+ 
predominance alongside a representation of highly differentiated γδ T  cells. The infil-
trating CD8β+ T cells displayed increased expression of the cytotoxic marker perforin 
when compared with the peripheral T-cell pool. Similarly, there was robust granzyme B 
staining localizing to the tumors; affirming the presence of cytotoxic immune cells within 
the tumor. In parallel with this antitumor immune response, the tumors displayed enrich-
ment in FOXP3-expressing T cells and increased gene expression of indoleamine 2,3- 
dioxygenase 1 (IDO1), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), and pro-
grammed death-ligand 1 (PDL1). Finally, we investigated the Oncopig immune system 
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inTrODUcTiOn
For decades, preclinical studies pertaining to novel cancer 
therapies have relied on animal models of disease. Traditionally, 
rodents have been the gold standard for cancer research providing 
invaluable insights into the interplay between the immune system 
and tumor cells. However, despite these numerous advances, 
mice often failed to fully recapitulate human cancers, and many 
promising preclinical therapies were unsuccessful in the clinic 
(1, 2). Beyond differences in disease pathogenesis and progres-
sion between rodents and humans (3–5), the size constraints of 
rodents often do not support the investigation of new surgical 
interventions (4, 6). In light of the numerous obstacles presented 
by rodent models of disease, alternative model systems have been 
proposed, including zebrafish (7, 8), cats (9), dogs (9–14), and pigs 
(15–22). Due to homology in physiology, anatomy, size, genetics, 
metabolism, life span, and immunome between humans and pigs 
(15, 23–25), a porcine model may be extremely relevant for pre-
clinical testing of cancer treatments. Furthermore, in contrast to 
murine cells, both porcine and human somatic cells demonstrate 
suppressed telomerase activity in most tissues that is reactivated 
during cancer development (26, 27). For this reason, induction 
of oncogenesis in humans and pigs generally requires a greater 
number of genetic defects than in mice (3, 6). To determine the 
relevance of the pig as a preclinical platform for immunotherapy, 
we employed the Oncopig model with inducible oncogenic RAS 
and dominant-negative P53 (28). Upon exposure to an adeno-
viral vector Cre-recombinase (AdCre), the infected cells of the 
transgenic Oncopig acquire two driver mutations: KRASG12D and 
TP53R167H; two of the most common genetic abnormalities in 
human cancer (28, 29). The ability of tumor cells to avoid immune 
destruction has been included as a hallmark of tumorigenesis 
(30). Toward this end, immune checkpoint inhibitors have dem-
onstrated tremendous promise in the clinic (31–33). However, 
when predicting patient responsiveness to such immunothera-
pies, the number and types of intratumoral immune cells are key 
factors (34–37). The Immunoscore suggests a new classification 
of cancer, where the tumor microenvironment plays an important 
role, and the relationship between intratumoral immune cells 
and patient prognosis is taken into account (38–40). This new 
approach currently serves as a prognostic tool for colorectal 
cancer; however, the universal applicability of the Immunoscore 
as a prognostic strategy in various cancer types remains to be 
fully validated (41). Given the importance of the intratumoral 
immune cells in both prognosis and response to therapy, we 
performed a characterization of the immunological landscape 
in Oncopig tumors to evaluate the applicability of the model for 
studying antitumor immune responses and for future testing of 
immunotherapies in a large and relevant in vivo system.
MaTerials anD MeThODs
Pigs
The KRASG12D and TP53R167H floxed Oncopigs (28) were neither sex- 
nor age-matched, and all animals were housed at the University of 
Illinois, Urbana-Champaign, United States. F1 animals (minipig 
carrying the transgene crossed with Yorkshire domestic pigs) 
heterozygous for the transgenes were used for experiments. A 
total of 27 animals were included. All animal experiments were 
carried out in accordance with both national and international 
guidelines. The University of Illinois Institutional Animal Care 
and Use Committee (IACUC; Protocol number 14126) approved 
all procedures.
adcre injections for Tumor induction
All animals were anesthetized using an intramuscular injec-
tion of Telazol®-Ketamine-Xylazine, 1  ml/50  lbs. The AdCre 
(Ad5CMVCre-eGFP, Gene Transfer Vector Core, University of 
Iowa, batch: Ad3500 or Ad3743, cat. no. VVC-U of Iowa-1174) 
was used for triggering tumors in vivo, and the preparation was 
previously described elsewhere (28, 42). Briefly, AdCre was 
diluted with minimal essential medium (Corning, cat. no. 50-011) 
containing 2 M calcium chloride resulting in a final concentration 
of calcium chloride of 0.01 M. Following dilution, the final con-
centration of AdCre ranged from 1 × 109 to 2 × 109 PFU/ml. The 
mixture was allowed to incubate at room temperature (RT) for 
15 min before injection. For all subcutaneous injections (flank), 
a total volume of 1  ml AdCre was injected. For intramuscular 
injections (leg), animals received 0.5 or 1 ml. All AdCre injec-
tions were carried out using a 21 gauge needle and completed 
within 45 min from the time of incubation. Each animal received 
between one and six AdCre injections at the same time to induce 
one or multiple tumors. Animals were monitored every second 
in mediating antitumor immunity. We observed pronounced killing of autologous tumor 
cells, which demonstrates the propensity of the Oncopig immune system to recognize 
and mount a cytotoxic response against tumor cells. Together, these findings suggest 
innate and adaptive recognition of the induced tumors with a concomitant in vivo sup-
pression of T-cell effector functions. Combined, the data support that the Oncopig may 
serve as a valuable model for future preclinical testing of immunotherapies aimed at 
reactivating tumor-directed cytotoxicity in vivo.
Keywords: porcine cancer model, comparative oncology, translational immunology, antitumor immunity, T cells, 
immunotherapy
Abbreviations: AdCre, adenoviral vector cre-recombinase; CTLA4, cytotoxic 
T-lymphocyte-associated protein 4; DMSO, dimethyl sulfoxide; FBS, fetal bovine 
serum; IDO1, indoleamine 2,3-dioxygenase 1; MDSCs, myeloid-derived suppres-
sor cells; NK, natural killer; PMBCs, peripheral blood mononuclear cells; PBS, 
phosphate buffered saline; PDL1, programmed death-ligand 1.
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day, and tumor measurements was carried out using a caliper. 
All animals were euthanized 7–21 days post AdCre injection; the 
exact time was depended on tumor size. For euthanasia, pigs were 
injected intracardially with 1 ml/5 kg body weight of Fatal-Plus® 
Solution (Vortech Pharmaceuticals, cat. no. 9373).
immunohistochemistry
Tissues were fixed in 10% formalin and paraffin-embedded. 
Slides were sectioned at 4 µm interval and all subsequent steps 
were carried out at RT. Heat-induced epitope retrieval was car-
ried out using a Menarini Access Retrieval Unit with a sodium 
citrate buffer (pH 6) for 1 min 40 s at 125°C, full pressure. The 
slides were then loaded onto a Dako Autostainer and rinsed with 
a Tris/Tween buffer (pH 7.5) before treatment with Dako Real 
TM Peroxidase blocking solution (Agilent Technologies, cat. 
no. S202386-2) for 5 min followed by buffer rinse (Tris/Tween, 
pH 7.5) for an additional 5 min. Slides were then treated with 
the primary antibody: Polyclonal Rabbit Anti-Human CD3 
(Agilent Technologies, cat. no. A045201-2) diluted in Dako 
universal diluent (Agilent Technologies, cat. no. S080981-2) 
and stained for 30 min. Two rounds of 5 min buffer rinse (Tris/
Tween, pH 7.5) were carried out before secondary staining with 
Dako EnVision  +  System-HRP Labeled Polymer Anti rabbit 
(Agilent Technologies, cat. no. K400211-2) for 30  min. The 
slides were then rinsed twice (Tris/Tween, pH 7.5) and treated 
with 3,3′-diaminobenzidine  +  substrate-chromogen system 
(Agilent Technologies, cat. no. K346889-2) for 10 min. Finally, 
the slides were washed thrice in H2O and counterstained with 
Gills Hematoxylin (Sigma-Aldrich, cat. no. GHS1128) for 27  s 
followed by additional wash in H2O.
immunofluorescence
Tissues were fixed in 10% formalin, embedded in paraffin, and 
sectioned at 4 µm intervals. For immunofluorescence, slides were 
heated in a pressure cooker using DAKO Target Retrieval Solution 
(Agilent Technologies, cat. no. S170084-2), blocked for 1 h at RT 
with Innovex Background Buster (Innovex, cat. no. NB306) with 
5% Fc Receptor Block (Innovex, cat. no. NB309) and incubated 
with primary antibodies against CD3 (Santa Cruz Biotech, cat. 
no. sc-20047), CD8α (Santa Cruz Biotech, cat. no. sc-7188), or 
Granzyme B (abcam, cat. no. ab134933) at 1:100–200 overnight 
at 4°C. Slides were mounted in a DAPI containing medium (Santa 
Cruz) and visualized using either Alexa Fluor 488 (abcam, cat. 
no. ab150113) or Alexa Fluor 594 (abcam, cat. no. ab150080) 
conjugated secondary antibodies.
cell isolation
Peripheral blood samples were collected from the jugular vein 
using BD sodium heparinized vacutainer tubes (BD Diagnostics, 
cat. no. 362753) and purified using SepMate tubes (StemCell 
Technologies, cat. no. 85450) according to the manufacturer’s 
protocol. Briefly, sodium heparinized blood was diluted 1:1 in 
phosphate buffered saline (PBS)/2% fetal bovine serum (FBS) 
(Thermo Fisher Scientific, cat. no. 10082147) before separation 
using Lymphoprep (StemCell Technologies, cat. no. 07851) with 
centrifugation settings at 12,00 × g for 20 min at 4°C. Cells were 
subsequently washed twice and counted using a hemocytometer. 
Viable cells were distinguished from dead cells using Trypan 
blue (Sigma-Aldrich, cat. no. T0887). To isolate cancer cells from 
in vivo-induced tumors; a 1 cm3 tumor biopsy was harvested and 
cut into small pieces before incubation in pre-heated RPMI-1640 
containing 2% FBS, 3  mg/ml Collagenase D (Sigma-Aldrich, 
cat. no. COLLD-RO), 5  µg/ml DNase I (Sigma-Aldrich, cat. 
no. 11284932001), and 1 µg/ml Dispase II (Sigma-Aldrich, cat. 
no. 04942078001) for 90  min at 37°C. Samples were vortexed 
every 30 min to facilitate digestion. Cells were then passed twice 
through a 70  µm cell strainer to obtain a single-cell suspen-
sion. Processing was completed within 6  h for all cells. Cells 
were counted using the Nucleocounter NC-200 (Chemometec, 
Allerød, Denmark), and 107 cells per vial of peripheral blood 
mononuclear cells (PBMCs) or tumor cells were cryopreserved 
for subsequent analysis. FBS/10% dimethyl sulfoxide (DMSO) 
was used as freezing medium, and every vial was placed in a Mr. 
Frosty freezing container at −80°C within 3 min of exposure to 
DMSO. The vials were transferred to liquid nitrogen 24 h later for 
long-term storage.
Flow cytometry
Antibodies were used at pre-determined optimal concentrations 
(Table S1 in Supplementary Material). Cryopreserved PBMCs and 
tumor cell suspensions were thawed in RPMI-1640/20% FBS and 
subsequently washed twice in PBS/0.5% FBS. The median viability 
post thawing was 91.7% as determined by the Nucleocounter 
NC-200, and ~4  ×  106 cells per sample were stained for flow 
cytometry. The samples were then surface stained for 30  min 
at 4°C with a combination of anti-CD3, anti-CD4, anti-CD8α, 
anti-CD8β antibodies, and a live/dead stain allowing viable cells 
to be distinguished from dead cells. For detection of γδ T cells, 
thawed cell suspensions were stained with a combination of 
anti-CD2, anti-TCR1 δ chain, anti-CD8α, and a live/dead stain. 
For detection of FOXP3, cells were fixed and permeabilized post 
surface staining using the Anti-Mouse/Rat Foxp3 Staining Set 
(Thermo Fisher Scientific, cat. no. 72-5775-40) according to the 
manufacturer’s protocol. Cells were then incubated with anti-
FoxP3 antibody for 30  min at 4°C. In performing intracellular 
cytokine staining, samples were first cultured for 16  h at 37°C, 
5% CO2 in RPMI-1640/10% FBS medium; serum was pretested 
in cell stimulation assays before use. As a positive control, 1 µg/ml 
phytohemagglutinin (Sigma-Aldrich, cat. no. L4144) was used 
for stimulation. To block cytokine secretion, cells were then cul-
tured for an additional 6 h in the presence of 10 µg/ml Brefeldin 
A (Sigma-Aldrich, cat. no. B7651-5MG). Following surface stain 
with antibodies (Table S1 in Supplementary Material), cells were 
then fixed using the Fixation/Permeabilization Solution Kit (BD 
Biosciences, cat. no. 554714) according to the manufacturer’s 
protocol, stained with a mixture of anti-IFN-γ, anti-TNF-α, and 
anti-perforin antibodies for 30 min at 4°C. KRASG12D was detected 
by flow cytometry using the Fixation/Permeabilization Solution 
Kit directly with no pre-culturing in the presence of Brefeldin A. 
In all staining procedures, fluorescence-minus-one controls were 
included. Samples were acquired using an LSR II (BD Biosciences, 
Albertslund, Denmark) or an LSRFortessa (BD Bioscience, 
Albertslund, Denmark) flow cytometer, and the PMT voltages 
were adjusted based on a mixture of unstained cells resulting in 
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a mean auto fluorescence intensity of ~102 for all fluorochromes. 
Outputs were analyzed using either FCS Express version 6 
(De Novo Software) or FlowJo Data Analysis Software version 10. 
The analysis was performed on viable, single cells (lymphocytes 
or tumor cells) (Figure S1A in Supplementary Material) with the 
following gating strategy being indicated in each figure legend. 
Examples of CD3, CD4, CD8β, CD8α, perforin, and FOXP3 
staining are shown in Figure S1B in Supplementary Material. All 
samples (a minimum of 200,000 T cells) were recorded for analysis.
In Vitro cytotoxicity
Freshly isolated PBMCs and tumor cells were washed twice with 
PBS to remove any serum and counted using the hemocytometer 
and Trypan Blue. Effector cells (PBMCs) remained unlabeled. 
Control cells (30 × 106 PBMCs) and target cells (30 × 106 isolated 
tumor cells) were labeled with 10  µM eFluor450® and 5  µM 
eFluor670® Cell Proliferation Dye (eBioscience, cat. no. 65-0842-
85 and 65-0840-85), respectively, according to the manufacturer’s 
protocol. Briefly, cells were labeled for 10 min at 37°C in the dark 
and labeling was stopped by adding four to five volumes of cold 
RPMI-1640/10% FBS. The cells were then incubated on ice for 
5 min covered in the dark followed by three washing steps with 
RPMI-1640/10% FBS. For culturing, a titration of effector:target 
cell ratio was carried out as follows: 0:1, 0.5:1, 1:1, and 2:1; 
culturing conditions were 37°C, 5% CO2 in 24-well plates. Each 
well contained a total of 3 × 106 cells. Samples were harvested at 
10 min and 24 h post coculturing, fixed immediately with a 4% 
paraformaldehyde solution (Fisher Scientific, cat. no. 199431LT) 
to eliminate additional killing or cell turnover. Notably, culture 
wells containing effector:control cells and effector:target cells 
were mixed only at the time of harvesting; samples were then fixed 
to stop potential additional killing or cell turn over and acquired 
straight away on the flow cytometer. Samples were washed twice 
in PBS/0.5% FBS and acquired using an LSR II (BD Biosciences) 
flow cytometer, and data were analyzed using FCS Express version 
6 (De Novo Software). PMT voltages were once again adjusted 
according to an unstained sample; the mean auto fluorescence 
value for each fluorochrome was adjusted to approximately 102. 
For each sample, ~1.5 × 106 cells were acquired for analysis. The 
percentage of specific killing was determined by comparing the 
percentage change ratio between control and target cell popula-
tions at baseline and 24 h post coculture. Individual animal values 
were normalized to background levels of killing/cell turnover 
from wells with no-effector cells added.
rna-seq analysis
Previously RNA-Seq datasets were produced for Oncopig primary 
hepatocyte cell lines (n = 3), transformed hepatocyte [hepatocel-
lular carcinoma (HCC)] cell lines (n = 3), primary fibroblast cell 
lines (n = 8), and transformed fibroblast (soft-tissue sarcoma) cell 
lines (n = 4) and were downloaded from the ENA database1 under 
accession number PRJEB8646 (43, 44). In addition, previously 
produced Oncopig skeletal muscle (n = 3) and leiomyosarcoma 
tumor (n =  4) RNA-Seq datasets were downloaded from the 
1 www.ebi.ac.uk/ena (Accessed: September 12, 2017).
ArrayExpress database2 under accession number E-MTAB-3382 
(28). All datasets consisted of paired-end 100  bp reads pro-
duced on an Illumina HiSeq2000 (E-MTAB-3382) or Illumina 
HiSeq2500 (PRJEB8646). Sequencing depths for each sample 
are provided in Table S3 in Supplementary Material. Raw reads 
were trimmed, aligned to the swine reference genome (45), and 
assessed for differential gene expression as previously described 
in Ref. (28, 43, 44). Briefly, reads were trimmed sequentially for 
adapter contamination, A-tails, and minimum quality score (20) 
and length (20 bp) using Trim Galore v.0.3.3,3 setting the strin-
gency option to 6. Trimmed reads were then aligned to the swine 
reference genome (Sscrofa10.2) using Tophat v.2.2.10 (46) with 
the -M, -G, fr-firststrand option, and setting the read-realign- 
edit-dist option to 0. Aligned bam files were assessed for differen-
tial gene expression using cufflinks v.2.2.1 (47). Transcripts were 
assembled using the fr-firststrand option and merged with the 
swine reference transcripts using Cuffmerge. Cuffdiff was used to 
assess differential expression for three comparisons (hepatocyte 
cell lines vs HCC cell lines, primary fibroblast cell lines vs soft-
tissue sarcoma cell lines, and skeletal muscle vs leiomyosarcoma 
tumors) using the -u and fr-firststrand options. Genes were 
considered differentially expressed with a q-value < 0.05.
statistical analysis
Despite low numbers of animals, the data were analyzed by para-
metric analyses as 80% of datasets showing a significant difference 
to baseline data passed the Shapiro–Wilk normality test. Results 
are shown as the mean ± SEM. Statistical comparisons of mean 
values were conducted using either paired or unpaired Student’s 
t-test depending on the experimental setup. All statistical analysis 
was carried out using GraphPad Prism version 7.00 for Windows 
(CA, USA). *P < 0.05 was considered significant. **P < 0.005 and 
***P < 0.001 are indicated. To take the false discovery rate into 
account, q-values rather than P-values were used for RNA-Seq 
analysis (44, 48). A q-value < 0.05 was considered significant.
resUlTs
KRASG12D-expressing Tumors are 
infiltrated by T cells
To confirm tumorigenesis in this porcine model, Oncopigs were 
subcutaneously injected into the flank with AdCre, whereupon 
a tumor could be excised 7–21 days post injection (Figure 1A). 
Since the CAG promoter controls the expression of the two 
mutated transgenes, KRASG12D and TP53R167H, showing the gene 
product of one or the other transgene is sufficient to confirm 
successful transformation. Therefore, the presence of KRASG12D 
was shown at the protein level using intracellular flow cytometry 
staining of single-cell suspensions obtained from tumor biopsies 
(Figure 1B). Having confirmed the ability to induce tumors in 
the Oncopig, we then examined for the presence of intratumoral 
T  cells. Tumor sections obtained from Oncopigs injected with 
AdCre at two different sites, subcutaneous (Figures 1C,D) and 
2 www.ebi.ac.uk/arrayexpress (Accessed: September 12, 2017).
3 http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/ (Accessed: September 
12, 2017).
FigUre 1 | Oncopig tumors are infiltrated by T cells. The KRASG12D and TP53R167H floxed Oncopigs were subcutaneously injected with AdCre to induce 
tumorigenesis. (a) Representative image of subcutaneous tumor formation in Oncopigs 7–21 days post subcutaneous injection into the flank of AdCre (n = 6), 
where n indicates the number of animals. (B) Representative intracellular flow cytometric plot of KRASG12D-expression in isolated tumor cells (white) with 
fluorescence-minus-one control indicated (gray). Oncopigs were subcutaneously into the flank (c,D) or intramuscularly into the leg (e,F) injected with AdCre,  
and tumor sections were harvested 20 days post injection. Representative immunohistochemistry images with detection of CD3+ cells at 10× (c,e) and 40×  
(D,F) magnifications are shown (n = 3), where n indicates the number of animals.
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intramuscular (Figures  1E,F), were immunohistochemistry 
stained for the common T-cell marker CD3. Independent of the 
site of AdCre administration, CD3+ cells were found to infiltrate 
the tumors. Since the site of AdCre administration did not affect 
the T-cell infiltration, subcutaneous tumors were used for the 
remaining parts of the study.
cD8β+ T cells Preferentially infiltrate 
Oncopig Tumors
Given that T cells infiltrate tumors as shown by immunohisto-
chemistry, the next step was to address which T-cell subsets were 
present and whether the intratumoral T-cell pool differed from 
FigUre 2 | CD8β+ T cells specifically infiltrate the established tumors. Oncopigs were subcutaneously injected with AdCre. PBMCs and tumor tissue were 
harvested 7–21 days post injection and analyzed using flow cytometry. Cells were pre-gated on viable, single lymphocytes. (a) Numbers represent CD3+ cells as  
a percentage of live cells. (B) Percentage of CD4+ cells in live, CD3+-gated cells. (c) Percentage of CD8β+ cells in live, CD3+-gated cells. (D) Percentage of CD8α+ 
cells in live, CD3+CD4+-gated cells. Bars represent mean values ± SEM, and data are from two independent experiments (n = 4–5), where n indicates the number  
of animals. Statistical evaluations were performed by unpaired Student’s t-test (*P < 0.05 and ***P < 0.001).
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the circulating counterpart. Using flow cytometry, quantification 
of the percentage of total (CD3+) T cells revealed no difference 
between peripheral blood and tumor cell isolates (Figure  2A); 
thus, indicating that PBMCs and tumor cell suspensions encom-
pass similar T cells levels. In contrast to other species, CD4+CD8+ 
double-positive T  cells comprise a significant proportion of 
circulating lymphocytes in the pig (49); and the vast majority of 
this subset expresses the CD8α homodimer which is now associ-
ated with activation of porcine CD4+ T cells (50). On the other 
hand, the expression of the CD8α/CD8β heterodimer is linked 
to conventional cytolytic CD8+ T cells (51). Comparison of the 
different T-cell subsets revealed that the amount of CD4+ T cells, 
as a percentage of total CD3+ cells, was similar in the tumor and 
in peripheral blood (Figure 2B). While a significant increase in 
percentage of CD8β+ T cells was found at the tumor site (mean 
values: 39.7% in contrast to 13.3% for the PBMC samples) 
(Figure 2C), the proportion of CD4+ T cells expressing the CD8α+ 
activation molecule was significantly reduced within tumor iso-
lates (Figure  2D). Combined, these data showed that Oncopig 
tumors were specifically infiltrated by cytotoxic CD8β+ T cells.
cytotoxic immune cells are represented 
in the Microenvironment of Oncopig 
Tumors
To further investigate the nature of the intratumoral T-cell sub-
sets in more detail, the production of perforin, TNF-α, and IFN-γ 
was evaluated in T cells derived from peripheral blood and tumor 
samples. Using flow cytometry, perforin-producing T cells were 
observed both in peripheral blood and within the tumor; how-
ever, a greater than fourfold increase in total perforin-producing 
T cells was observed in the tumor samples over peripheral blood 
samples (mean values: 26.9 vs 5.8%) (Figure 3A). T cells producing 
TNF-α or IFN-γ were not detectable without further stimulation 
(data not shown). CD4+ T cells, as expected, produced only very 
limited amounts of perforin, and no differences were observed 
in perforin+CD4+ T  cells between the PBMC and the tumor 
samples (Figure 3B). By contrast, a perforin+CD8β+ T-cell popu-
lation was clearly detected in the tumor with nearly a threefold 
increase compared with peripheral blood (Figure 3C); indicating 
a cytotoxic infiltration to the tumor. To further corroborate this 
observation, immunofluorescence using formalin-fixed tumor 
sections was performed. First, the infiltration of CD3+ cells 
previously observed (Figures 1C–F) was confirmed (Figure 3D). 
Second, co-localization of the CD3 and the CD8α marker 
within the tumor was demonstrated (Figure  3E). Importantly, 
intratumoral granzyme B+ cells were visualized (Figure  3F); 
thereby, confirming the presence of cytotoxic cells within the 
tumor. The percentages of CD4+, CD8β+, and perforin+CD8β+ 
T cells in peripheral blood did not reveal any difference between 
tumor bearing and non-tumor bearing pigs (Figures S2A–C in 
Supplementary Material). The representation of natural killer 
(NK) cells (CD3−CD4−CD8α+) revealed no significant differences 
between the NK-cell percentage in PBMCs and intratumoral cell 
isolates (Figure S2D in Supplementary Material).
Oncopig Tumors are specifically 
infiltrated by a Distinct subset of  
γδ T cells
While conventional αβ T cells have received a lot of attention, 
γδ T  cells have been much less studied, although they have 
been demonstrated to have implications in cancer (52). As γδ 
T  cells represent a major porcine T-cell population (53, 54), 
we set to determine the potential presence of this immune cell 
subset in Oncopig tumors. Using flow cytometry, we once again 
compared peripheral blood and tumor isolates. First, and by use 
of an antibody detecting the δ chain of the T-cell receptor (55) 
(Table S1 in Supplementary Material), γδ T cells were detected 
in viable, single-cell suspensions (Figure  4A). A comparison 
between PBMC and tumor samples revealed a significant 
reduction in the total representation of γδ T  cells within the 
tumor (Figure 4B). In pigs, the different γδ T-cell subsets and 
their functional differentiation are traditionally defined by their 
expression of CD2 and CD8α (56). Using flow cytometry, the 
expression level of CD2 and CD8α in γδ T cells was evaluated in 
both PBMC and tumor samples (Figure 4C). Comparison of the 
different γδ T-cell subsets revealed a significant decrease in the 
representation of CD2−CD8α− cells in Oncopig tumors com-
pared with blood levels (Figure 4D), while no difference between 
the two sites was observed when comparing CD2−CD8α+ cells 
(Figure 4E) or CD2+CD8α− cells (Figure 4F). Interestingly, a 
FigUre 3 | The tumor microenvironment of Oncopigs is infiltrated by perforin+ and granzyme B+ immune cells. Oncopigs were subcutaneously injected with AdCre 
to induce tumor formation. PBMCs and tumor samples were harvested 7–21 days post injection and analyzed by flow cytometry. Cells were pre-gated on viable, 
single lymphocytes. (a) Numbers represent perforin+ cells as a percentage of live CD3+-gated cells. (B) Percentage of perforin+ cells in live, CD3+CD4+-gated cells. 
(c) Perforin+ cells as a percentage of live, CD3+CD8β+-gated cells. Bars represent mean values ± SEM, and data are from two independent experiments (n = 4–5). 
Statistical evaluations were performed by unpaired Student’s t-test. (D) Tissue sections were harvested from Oncopig tumors isolated 7–21 days post AdCre 
injection. Detection of CD3+ cells (green) in a tumor cross-section by immunofluorescence. (e) Immunofluorescence image detecting co-localization of CD3+  
(green) and CD8α+ (red) cells in the tumor. (F) Detection of granzyme B+ cells (red) in a tumor cross-section. DAPI (blue) used as nuclear counterstain for all 
immunofluorescence images (*P < 0.05).
FigUre 4 | An increased representation of CD2+CD8α+ γδ T cells is found within Oncopig tumors. Oncopigs were subcutaneously injected with AdCre. 
 Peripheral blood and tumor samples were harvested 7–21 days post injection and analyzed by flow cytometry. All cells were pre-gated on viable, single 
lymphocytes. (a) γδ T cells were detected by expression of the δ chain of the T cell receptor in viable, single lymphocytes. Representative flow cytometric plot is 
shown. (B) Representation of γδ T cells as a percentage of viable, single lymphocytes in tumor and peripheral blood. (c) Representative flow cytometric plots of 
CD2 and CD8α expression in γδ T cells obtained from peripheral blood (left plot) and tumor isolates (right). (D) Percentage of CD2−CD8α− cells in viable γδ T cells. 
(e) Percentage of CD2−CD8α+ cells in viable γδ T cells. (F) Percentage of CD2+CD8α− cells in viable γδ T cells. (g) Percentage of CD2+CD8α+ cells in viable γδ 
T cells. Bars represent mean ± SEM, and data are from one experiment (n = 5). Statistical evaluations were performed by paired Student’s t-test (*P < 0.05 and 
**P < 0.005).
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TaBle 1 | Elevated IDO1, CTLA4, and PDL1 expression in Oncopig tumors.
gene skeletal muscle (FPKM) leiomyosarcoma (FPKM) log2 fold change P-value q-Value significant
IDO1 0.49 3.8 3.0 5.00E−05 0.00023 Yes
CTLA4 0.13 1.0 2.9 5.00E−05 0.00023 Yes
PDL1 0.34 1.1 1.7 0.00075 0.0028 Yes
Gene expression was determined by RNA-Seq analysis with comparison of normal skeletal muscle tissue and AdCre-induced leiomyosarcoma. Expression values are given as 
fragments per kilobase of transcript per million mapped reads (FPKM). q-Value <0.05 is considered significant.
CTLA4, cytotoxic T-lymphocyte-associated protein 4; IDO1, indoleamine 2,3-dioxygenase 1; PDL1, programmed death-ligand 1.
FigUre 5 | Oncopig tumors display increased levels of FOXP3+ T cells. Oncopigs were subcutaneously injected with AdCre. Peripheral blood and tumor samples 
were harvested 7–21 days post injection and analyzed for intracellular expression of FOXP3 by flow cytometry. Cells were pre-gated on viable, single lymphocytes. 
(a) Percentage of FOXP3+ cells in live, CD3+-gated cells. (B) Percentage of FOXP3+ cells in live, CD4+CD8α− gated T cells. (c) Percentage of FOXP3+ cells in live, 
CD4+CD8α+-gated T cells. (D) Percentage of FOXP3+ cells in live, CD4−CD8α+-gated T cells. All bars represent mean values ± SEM, and data are from one 
experiment (n = 5). Statistical evaluations were performed by paired Student’s t-test (*P < 0.05).
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Oncopig Tumors show elevated IDO1, 
CTLA4, and PDL1 expression levels
In addition to the presence of FOXP3+ T  cells within Oncopig 
tumors, we determined if other intratumoral immunoregula-
tory mechanisms were present. Indoleamine 2,3-dioxygenase 1 
(IDO1), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), 
and programmed death-ligand 1 (PDL1) encode for proteins 
that are activated during tumor development in humans and 
play a role in suppressing immune responses, ultimately helping 
malignant cells escape T-cell mediated killing. To determine if 
these genes are upregulated in Oncopig tumors, expression levels 
were investigated using previously produced Oncopig RNA-Seq 
datasets (28, 43, 44). As expected, increased expression of IDO1, 
CTLA4, and PDL1 was observed in Oncopig leiomyosarcoma 
tumors relative to control muscle samples (Table 1). No increased 
expression was observed in Oncopig transformed cell lines (HCC 
and fibroblasts) compared with primary non-transformed cell 
lines, indicating the increased expression observed in Oncopig 
tumors is not simply a result of cellular transformation (Table S2 
in Supplementary Material). Together, these data indicate a sup-
pressive role for IDO1, CTLA4, and PDL1 within Oncopig tumors.
autologous Tumor cells are specifically 
lysed by the Oncopig immune system 
In Vitro
Having shown the presence of both cytotoxic and regulatory 
immune cells within Oncopig tumors, we set to determine if the 
Oncopig immune system was capable of mediating direct antitumor 
immunity outside of an immunosuppressive microenvironment. 
For this reason, we developed an in  vitro fluorescence-based 
fourfold increase in the percentage of γδ T cells displaying the 
CD2+CD8α+ phenotype was detected in tumors compared with 
blood (Figure  4G); mean values: 51.1% in tumor isolates in 
contrast to 12.8% for the PBMC samples. Combined, these data 
show that Oncopig tumors are infiltrated by γδ T cells with a 
distinct CD2+CD8α+ phenotype compared with the circulating 
counterpart.
increased levels of FOXP3+ T cells  
are Found Within Oncopig Tumors
Tumor microenvironments often contain a mixture of immune 
cells. In addition to the cytotoxic immune cell subsets and γδ 
T cells, which were shown to be present, we tested for regulatory 
T cells using flow cytometric detection of the FOXP3 marker. A 
pronounced population of T cells expressing FOXP3 was read-
ily detected in both blood samples and within tumors. When 
comparing these two sites, a significant elevated representation 
of FOXP3+ T cells was detected within the tumors (Figure 5A), 
suggesting an intratumoral regulatory compartment. Similar 
percentages of CD4+CD8α−FOXP3+ T cells were observed when 
comparing blood and tumor isolates (mean values: 10.1 and 
12.9%) (Figure 5B). Although not significant due to high animal 
to animal variation, a strong tendency toward an increased 
amount of CD4+FOXP3+ T cells expressing the CD8α activation 
marker was observed in the tumor when compared with circulat-
ing blood (mean values: 16.0 and 2.1%) (Figure 5C). By contrast, 
the circulating T-cell pool comprised a slightly higher amount of 
potential regulatory CD4−CD8α+FOXP3+ T  cells; although the 
percentages were low in general (Figure 5D). Together, these data 
suggest that Oncopig tumors also encompass an active regulatory 
T-cell compartment.
FigUre 6 | The Oncopig immune system specifically lyses autologous tumor 
cells in vitro. Oncopigs were subcutaneously injected with AdCre to induce tumor 
formation. Following tumor development (7–21 days post injection), tumor cells 
and PBMCs were harvested. Isolated effector cells remained unlabeled with 
control cells and tumor cells being labeled with eFluor670 or eFluor450, 
respectively. (a) Representative flow cytometric plots of control and tumor cells at 
10 min (baseline, left plot) and 24 h (right plot) post coculture. (B) Numbers 
represent percentage specific killing of autologous tumor cells; data were 
normalized to adjust for cell turnover in no-effector cells control cultures. A titration 
of the effector:target cell ratio is shown. Data are pooled from four independent 
experiments (n = 8). Bars represent mean values ± SEM. Statistical evaluations 
were performed by paired Student’s t-test (*P < 0.05 and **P < 0.005).
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cytotoxicity assay to allow the investigation of potential immune-
mediated killing of autologous tumor cells. Isolated effector cells 
were cocultured with either autologous targets or autologous 
control cells, and specific killing was monitored by flow cytometry. 
PBMCs were used as control cells, since both healthy, adjacent 
skin and muscle cells isolated from the same site as the tumor did 
not allow a clear fluorescence separation. A twofold titration of the 
effector:target cell ratio was performed ranging from 0:1 to 2:1. To 
determine lysis of the tumor cells, samples were harvested 10 min 
(Figure 6A, left plot) and 24 h post coculture (Figure 6A, right 
plot), and the percentage of specific tumor cell killing was quanti-
fied relative to the 10 min baseline. Each sample was normalized 
to its 0:1 effector:target control sample. Significant percentages of 
specific tumor cell killing were observed in an effector:target cell 
ratio dependent manner (Figure 6B), thereby, for the first time 
directly showing an endogenous porcine anti-cancer immune 
response in the Oncopig model.
DiscUssiOn
Although valuable, mice have several inherent limitations in 
cancer research. In addition to size and anatomical constraints, 
inbred rodents also do not fully mimic the diversity seen in human 
patients. Therefore, to establish a supplementary and large pre-
clinical model, we performed our studies in the Oncopig; increas-
ing diversity by using non-sex- and non-age-matched animals and 
restricting the use of littermates. Given the homology between the 
porcine and human immune system (24), the fully immunocom-
petent Oncopig may be an excellent platform studying antitumor 
immune responses and for preclinical investigation of cancer 
immunotherapies. To begin to assess the validity of the Oncopig 
model, we induced mutant transgene expression and tumor 
formation by subcutaneous delivery of AdCre. Theoretically, an 
increase in percentages of a certain immune cell subset within the 
tumor could result from either a consistent infiltration of these 
cells over time, intranodal proliferation, or efflux of other immune 
cell subsets from the tumor. For this reason, we do not conclude on 
exact numbers but report important differences in the representa-
tion of various T-cell subsets between the tumor and peripheral 
blood.
Following exposure to AdCre and tumor development, the 
resulting tumor microenvironment was infiltrated by T  cells 
displaying in particular a cytotoxic phenotype as deter mined by 
the expression of CD8β, the porcine marker for cytolytic T cells 
(51) while activated CD4 T  cells (CD4+CD8α+) were reduced 
relative to the representation in peripheral blood. Although 
antitumor immune responses are often evaluated using IFN-γ as 
readout, granzyme B and perforin release are two highly specific 
measures of antitumor cytotoxicity (57–61). We observed pro-
nounced intratumoral granzyme B production and increased 
levels of perforin-producing T  cells within Oncopig tumors. 
Finally, we showed the capacity of the Oncopig immune system 
to mediate tumor-specific lysis in  vitro; further supporting the 
presence of an adaptive antitumor immune response. Although 
we show pronounced infiltration of various T-cell subsets to the 
tumors, the antitumor immune responses demonstrated in our 
in  vitro cytotoxicity could be mediated by other immune cell 
subsets present in the PBMC culture. Potential other subsets, 
which might mediate the antitumor response, include NK cells, 
γδ T  cells, and natural killer T  cells. In fact, porcine NK  cells 
have been shown to display antitumor activities against a human 
cancer cell line (62); however, we did not observe in vivo specific 
NK-cell infiltration to the tumor site compared with the repre-
sentation found in circulation. Despite not specifically enriched 
in the tumor, these intratumoral NK cells may still play a role. As 
T cells are key players in mediating antitumor immune responses 
(63–65), the significant infiltration of cytotoxic T cells and highly 
differentiated γδ T  cells to Oncopig tumors clearly suggest a 
role for these immune cell subsets in facilitating tumor-specific 
lysis. To fully evaluate the role of conventional T cells in Oncopig 
antitumor immunity, blocking the MHC presentation pathway 
will be an interesting future approach as well as depletion studies 
of the various T-cell subsets.
In addition to the infiltration of cytotoxic T cells, we showed 
intratumoral enrichment of a CD2+CD8α+ γδ T-cell subset. 
Traditionally, porcine γδ T  cells have been divided into three 
distinct subsets based on their expression of the CD2 and CD8α 
markers, including CD2−CD8α−, CD2+CD8α−, and CD2+CD8α+ 
cells (56). The CD2−CD8α+ cells remain undescribed. Our data 
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support previous findings showing that the CD2−CD8α− cells 
are the most commonly found γδ T cells in circulating porcine 
blood (66, 67). This subset has been reported to comprise up 
to 90% of the total γδ T-cell population in peripheral blood 
(68), which is in line with our results (mean value: 79.9%). By 
contrast, CD2+CD8α− and CD2+CD8α+ γδ T  cells have been 
reported to preferentially home to the lymphoid tissues (66). As 
the CD2+CD8α− cells become more differentiated, they acquire 
CD8α expression (69); consequently, the CD2+CD8α+ cells are 
considered the highly differentiated γδ T-cell subset (56, 68). 
Although γδ T  cells have been shown to have implications in 
cancer, the nature of the tumor antigens recognized by γδ T cells 
remains fairly unknown in both human cancer and murine tumor 
models (52). The significant enrichment of highly differentiated 
γδ T cells found in Oncopig tumors clearly supports a role for 
this immune cell subset, and future studies should elucidate their 
specific role within tumor microenvironment.
FOXP3+ T  cells are common regulators of cytotoxic T-cell 
responses, and high levels of peripheral CD4+CD25+FOXP3+ 
regulatory T cells have been associated with poor clinical response 
to adoptive cell therapy in human cancer (70). We observed a 
robust subpopulation of T cells expressing FOXP3, both systemi-
cally as well as in the induced tumors. Recent findings suggest 
that human T helper cells can transiently upregulate FOXP3 upon 
activation, although only the T  cells stably expressing FOXP3 
were found to exhibit a suppressive nature (71). Therefore, the 
detection of FOXP3 in various intratumoral T-cell subsets in the 
Oncopig might indicate the presence of newly activated T cells. 
However, it is well established that FOXP3 is required for the 
development and maintenance of suppressive regulatory T cells 
(72, 73). Moreover, FOXP3 has been suggested as an exclusive 
marker for the CD4+CD25+ regulatory T-cell lineage in mice 
(74), and a suppressive CD8α+CD25+FOXP3+ T-cell subset has 
recently been observed in both mice and humans (75). The signifi-
cant infiltration of FOXP3-expressing T cells to the tumor mass 
suggest a regulatory role for this these immune cells in Oncopig 
tumors. In addition to the FOXP3+ T cells, increased expression 
of the immunosuppressive genes IDO1, CTLA4, and PDL1 was 
observed in Oncopig tumors but not in Oncopig-derived cell 
lines transformed in vitro. The lack of elevated expression in vitro 
indicates these genes are not simply upregulated as a result of 
cellular transformation, but rather in response to signals from 
the in vivo tumor microenvironment. The increased expression 
of IDO1, CTLA4, and PDL1 in Oncopig tumors thus indicates 
suppression of T cells in vivo. Another important immune cell 
subset with the capacity to dampen antitumor T-cell responses 
is the myeloid-derived suppressor cells (MDSCs). Within the 
tumor microenvironment, MDSCs are often present and effi-
ciently inhibit effector T-cell function by depletion of cysteine; 
an essential amino acid for T-cell activation (76). Moreover, 
MDSCs can limit T-cell functions by production of reactive 
oxygen species, arginase, and nitric oxide (77–79). Future stud-
ies should evaluate the role of these innate immune cells within 
Oncopig tumors.
Altogether, these findings suggest that within Oncopig tumors 
an antitumor immune response, dominated by cytotoxic T cells 
and differentiated γδ T cells, develop in parallel with a regulatory 
response mediated by FOXP3+ T  cells and elevated expression 
of immunosuppressive genes. As a spontaneous porcine model 
of melanoma displays a high rate of tumor regression over time 
(19), it will be important to investigate whether this antitumor 
immunity shown here in vitro becomes dominant over time in 
the Oncopig model or remains suppressed in vivo.
The porcine immunome and inflammasome shares a large 
homology with humans while the murine set of immune response 
genes is characterized by redundancy in terms of addition of many 
unique genes (24, 80). Other human to pig differences include the 
larger proportion of circulating γδ T cells and CD4+CD8+ T cells 
in porcine peripheral blood (50), and anatomical differences such 
as the inversion of the lymph node architecture, with resulting 
difference in lymphocyte recirculation, and a distinct porcine 
ileal Peyer’s patch (81). Importantly, it remains to be determined 
how these similarities and differences in gene expression circu-
lating lymphocyte subsets and anatomy are reflected biological 
function.
In conclusion, we for the first time showed that the Oncopig 
immune system is capable of recognizing the AdCre-induced 
tumors and responding with the development of antitumor 
responses specifically able to lyse autologous tumor cells in vitro 
as well as immunological regulatory responses in line with known 
escape mechanisms for cancer immunoediting (82). Combined, 
we believe that the Oncopig with its fully competent immune sys-
tem and homology with humans provides a crucial platform for 
studying antitumor immune responses with potential for future 
preclinical testing of immunotherapies aimed at reactivating the 
antitumor immune responses observed in vitro.
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